

PCT/H 0 3 / 0 0 7 2 8
4 MAR 2005



REC'D 30 SEP 2003

WIPO PCT

מדינת ישראל
STATE OF ISRAEL

Ministry of Justice
Patent Office



משרד המשפטים
לשכת הפטנטים

This is to certify that
annexed hereto is a true
copy of the documents as
originally deposited with
the patent application
of which particulars are
specified on the first page
of the annex.

זאת לתעודה כי
רוצפים בזו העתקים
נכונים של המסמכים
שהופקרו למבחן לה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנפקה.

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



נתאזר
Certified

BEST AVAILABLE COPY

PCT REQUEST

14729/WO/02

Original (for SUBMISSION) - printed on 04.09.2002 06:12:01 PM

0	For receiving Office use only International Application No.	PCT/IL 0 2 / 0 0 7 3 6
0-2	International Filing Date	04 SEP 2002 (04.09.02)
0-3	Name of receiving Office and "PCT International Application"	ISRAEL PATENT OFFICE PCT International Application
0-4	Form - PCT/RO/101 PCT Request Prepared using	PCT-EASY Version 2.92 (updated 01.06.2002)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	Israel Patent Office (RO/IL) RC
0-7	Applicant's or agent's file reference	14729/WO/0201
I	Title of invention	COMPOSITIONS COMPRISING BONE MARROW CELLS, DEMINERALIZED BONE MATRIX AND RTG POLYMERS FOR USE IN THE INDUCTION OF BONE AND CARTILAGE FORMATION
II	Applicant	applicant only
II-1	This person is:	all designated States except US
II-2	Applicant for	YISSUM RESEARCH DEVELOPMENT COMPANY OF
II-4	Name	THE HEBREW UNIVERSITY OF JERUSALEM
II-5	Address:	Hi Tech Park The Hebrew University of Jerusalem Edmond J Safra Campus, Givat Ram P.O. Box 39135 91390 Jerusalem Israel
II-6	State of nationality	IL
II-7	State of residence	IL
III-1	Applicant and/or Inventor	applicant only
III-1-1	This person is:	all designated States except US
III-1-2	Applicant for	HADASIT MEDICAL RESEARCH SERVICES &
III-1-4	Name	DEVELOPMENT LTD.
III-1-5	Address:	P.O. Box 12000 91120 Jerusalem Israel
III-1-6	State of nationality	IL
III-1-7	State of residence	IL

PCT REQUEST

14729/WO/02

Original (for SUBMISSION) - printed on 04.09.2002 06:12:01 PM

III-2	Applicant and/or inventor	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	SLAVIN, Shimon
III-2-5	Address:	21 Oren Street Ein Kerem 95744 Jerusalem Israel
III-2-6	State of nationality	IL
III-2-7	State of residence	IL
III-3	Applicant and/or inventor	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	GUREVITCH, Olga
III-3-5	Address:	25/14 Nurit Street Ir Ganim 96510 Jerusalem Israel
III-3-6	State of nationality	IL
III-3-7	State of residence	IL
III-4	Applicant and/or inventor	
III-4-1	This person is:	applicant and inventor
III-4-2	Applicant for	US only
III-4-4	Name (LAST, First)	KURKALLI, Basan Gowda S.
III-4-5	Address:	Leiberman Family Student Dormitories #4-3116 Hebrew University of Jerusalem Givat Ram Campus 95701 Jerusalem Israel
III-4-6	State of nationality	IN
III-4-7	State of residence	IL
III-5	Applicant and/or inventor	
III-5-1	This person is:	applicant and inventor
III-5-2	Applicant for	US only
III-5-4	Name (LAST, First)	COHN, Daniel
III-5-5	Address:	1 Motzkin Street 96551 Jerusalem Israel
III-5-6	State of nationality	IL
III-5-7	State of residence	IL

PCT REQUEST

Original (for SUBMISSION) - printed on 04.09.2002 06:12:01 PM

14729/WO/02

III-6	Applicant and/or Inventor	
III-6-1	This person is:	
III-6-2	Applicant for	
III-6-4	Name (LAST, First)	
III-6-5	Address:	
III-6-6	State of nationality	
III-6-7	State of residence	
IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	
IV-1-1	Name (LAST, First)	
IV-1-2	Address:	
IV-1-3	Telephone No.	
IV-1-4	Facsimile No.	
IV-1-5	e-mail	
IV-2	Additional agent(s)	
IV-2-1	Name(s)	
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	
	AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT	

PCT REQUEST


14729/WO/02

Original (for SUBMISSION) - printed on 04.09.2002 06:12:01 PM

V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW	
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.		
V-6	Exclusion(s) from precautionary designations	NONE	
VI	Priority claim	NONE	
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)	
VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	5	-
IX-2	Description	54	-
IX-3	Claims	6	-
IX-4	Abstract	1	EZABST00 .TXT
IX-5	Drawings	10	-
IX-7	TOTAL	76	
IX-8	Accompanying Items	paper document(s) attached	electronic file(s) attached
IX-17	Fee calculation sheet	✓	-
	PCT-EASY diskette	-	Diskette

PCT REQUEST

Original (for SUBMISSION) - printed on 04.09.2002 06:12:01 PM

IX-19	Figure of the drawings which should accompany the abstract	
IX-20	Language of filing of the International application	English
X-1	Signature of applicant, agent or common representative	
X-1-1	Name (LAST, First)	HACKNEY, Michal

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported International application	04 SEP 2002 (04.09.02)
10-2	Drawings:	
10-2-1	Received	✓
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported International application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	✓

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

PCT (ANNEX - FEE CALCULATION SHEET)

14729/WO/02

Original (for SUBMISSION) - printed on 04.09.2002 06:12:01 PM

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only			
0-1	International Application No.	PCT/IL 02/00736		
0-2	Date stamp of the receiving Office	04 SEP 2002 (04.09.02)		
0-4	Form - PCT/RO/101 (Annex) PCT Fee Calculation Sheet Prepared using	PCT-EASY Version 2.92 (updated 01.06.2002)		
0-9	Applicant's or agent's file reference	14729/WO/02		
2	Applicant	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, et al.		
12	Calculation of prescribed fees	fee amount/multiplier	Total amounts (USD)	Total amounts (ILS)
12-1	Transmittal fee	T	⇒	459
12-2-1	Search fee	S	⇒	866
12-2-2	International search to be carried out by	EP		
12-3	International fee			
	Basic fee (first 30 sheets)	b1	407 USD	
12-4	Remaining sheets		46	
12-5	Additional amount (X)		9 USD	
12-6	Total additional amount	b2	414 USD	
12-7	b1 + b2 =	B	821 USD	
12-8	Designation fees			
	Number of designations contained in international application		94	
12-9	Number of designation fees payable (maximum 5)		5	
12-10	Amount of designation fee (X)		88 USD	
12-11	Total designation fees	D	440 USD	
12-12	PCT-EASY fee reduction	R	-125 USD	
12-13	Total International fee (B+D-R)	I	⇒	1,136
12-17	TOTAL FEES PAYABLE (T+S+I+P)		⇒	2,002
12-19	Mode of payment	cash		

VALIDATION LOG AND REMARKS

13-2-1	Validation messages Request	Green? The title of the invention shall be short and precise. Please verify.
13-2-3	Validation messages Names	Green? Applicant 1.:Telephone No. missing
		Green? Applicant 1.:Facsimile No. missing

PCT (ANNEX - FEE CALCULATION SHEET)

Original (for SUBMISSION) - printed on 04.09.2002 06:12:01 PM

14729/WO/02

		Green? Applicant 5.: Where several first/given names are indicated, they should preferably be separated by a comma. Please verify.
13-2-4	Validation messages Priority	Green? No priority of an earlier application has been claimed. Please verify
13-2-7	Validation messages Contents	Yellow! The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
		Green? The abstract appears to be more than 150 words, applicant is reminded that it should be as concise as the disclosure permits (preferably 50 to 150 words if it is in English or when translated into English)
		Green? Figure of the drawings which should accompany the abstract not specified. Please verify.
13-2-8	Validation messages Fees	Green? Please confirm that fee schedule utilized is the latest available
13-2-1 1	Validation messages For receiving Office/international Bureau use only	Green? Verify electronic data for consistency against printed form.

COMPOSITIONS COMPRISING BONE MARROW CELLS, DEMINERALIZED BONE MATRIX AND RTG POLYMERS FOR USE IN THE INDUCTION OF BONE AND CARTILAGE FORMATION

Field of the Invention

The present invention relates to compositions comprising bone marrow cells (BMC) and demineralized bone matrix (DBM), supplemented with a reverse thermogelating polymer (RTG), and to their novel uses in induction of new bone and cartilage formation in mammals.

Background of the Invention

New bone formation, such as in the case of damage repair or substitution of a removed part of the bone in postnatal mammals, can only occur in the presence of the following three essential components, (i) mesenchymal progenitor cells; (ii) a conductive scaffold for these cells to infiltrate and populate; and (iii) active factors inducing chondro- and osteogenesis. In addition, for successful repair or replenishment of damaged hard tissues having definite mechanical functions, integrity and stability of the shape should be conferred to the transplant, withstanding mechanical forces during the period of tissue regeneration. Unfortunately, local conditions usually do not satisfy the requirements of osteogenesis, and thus substitution of removed, damaged or destroyed bones does not occur spontaneously.

Previous research has already uncovered somewhat about these three components.

It was shown that multipotent mesenchymal stem cells, which are capable of extensive proliferation and differentiation into cartilage, bone, tendon, muscle, fat and etc. are present in the bone marrow [Caplan, A.I. (1991) *J Orthop Res* 9:641-650; Prockop J.D. (1997) *Science* 276:71-74; Pittehger, M.F.

et al. (1999) *Science* 284:143-147; Wakitani, S.W. *et al.* (1995) *Muscle & Nerve* 18:1417-1426].

DBM has been shown to play the role of supportive material or structure that is essential for promoting engraftment of mesenchymal progenitor cells and their proliferation and differentiation in the course of bone and cartilage development, whenever mesenchymal cells are introduced as a cell suspension (Inventors' unpublished results). It serves as a conductive scaffold for cartilage and bone regeneration, while providing a natural source for inducing both chondro- and osteogenesis, thus combining all the essential inductive and conductive features. DBM also has additional advantageous, that can be summarized as follows: (i) it is mechanically flexible and slowly biodegradable, with the degradation time compatible with the period of *de novo* chondro- and osteogenesis; (ii) it is strong enough to provide at least partially biomechanical properties of the flat bone and joint surface during the period of new bone and cartilage formation; (iii) it can be provided as an amorphous powder that can be inserted locally, without major surgical intervention, while avoiding iatrogenic damage; (iv) it is a low immunogenic material even when used as a xenograft, and when used in an allogeneic combination, it is practically non-immunogenic [Block, J.E. and Poser, J. (1995) *Med Hypotheses* 45(1):27-32; Torricelli, P. *et al.* (1999) *Int Orthop* 23(3):178-81; Hallfeldt, K.K. *et al.* (1995) *J Surg Res* 59(5):614-20].

DBM is also a natural source for Bone Morphogenic Proteins - growth factors that play an important role in the formation of bone and cartilage [Ducy, P. and Karsenty, G. (2000) *Kidney Int* 57(6):2207-14; Schmitt, J.M. *et al.* (1999) *J Orthop Res* 17(2):269-78]. Most importantly, DBM is a natural source of BMPs. Moreover, induction of cartilage and bone may be enhanced by additional exogenous supply of BMPs that are not even species-specific [Sampath, T.K. and Reddi, A.H. (1983) *Proc Natl Acad Sci USA* 80(21): 6591-5; Bessho, K. *et al.* (1992) *J Oral Maxillofac Surg* 50(5):496-501], together

with DBM [Niederwanger, M. and Urist, M.R. (1996) *J Oral Implantol* 22(3-4):210-5].

Arthropathies are a group of chronic progressive joint diseases that can result from degenerative changes in the cartilage and hypertrophy of bone at the articular margins. Arthropathies can be secondary to trauma, inflammatory (autoimmune or infectious), metabolic or neurogenic diseases. Hereditary and mechanical factors may be an additional factor involved in the pathogenesis of arthropathies.

Restoration of a healthy joint surface in a damaged or degenerative arthropathy requires addressing the treatment both towards the cartilage and the subchondral bone.

Various attempts have been made to replace damaged cartilage, including:

1. Stimulation of bone marrow from subchondral bone to form a fibrotic repair tissue;
2. Osteochondral transplantation (allogeneic and autologous);
3. Transplantation of autologous cultured chondrocytes or mesenchymal cells;
4. Combined transplantation of chondrocytes with different kinds of matrices; and
5. Artificial implantation of mechanical joints.

Each of these methods has limitations and disadvantages and most of them are expensive, cumbersome, ineffective and rather impractical. Autologous osteochondral graft is restricted to a small area of damaged cartilage, up to 2 cm², and could cause discomfort, infection and morbidity in the donor site. Allogeneic osteochondral graft is immunogenic, hence requires life-long use of undesired, hazardous immunosuppressive agents, which would be an impractical approach for routine orthopedic practice. Transplantation of

cultured chondrocytes is cumbersome and very expensive, involving a two-stage procedure. The hyaline-like tissue which is produced after transplantation has sub-optimal biomechanical properties [Gilbert, J.E. (1998) *Am J Knee Surg* 11(1):42-6; Temeno, J. S. and Mikos, A. G. (2000) *Biomaterials: Tissue Engineering for Regeneration of Articular Cartilage*, 21:431-440; Buckwalter, J.A. and Mankin, H.J. (1998) *Instr Course Lect* 47:487-504; Stocum, D.L. (1998) *Wound Repair Regen.* 6(4):276-90]. Hence, adequate restoration of cartilage remains an unsolved problem.

Currently, autologous grafts are the most commonly used bone and cartilage graft material. However, the use of autografts has limitations, such as donor site discomfort, infection and morbidity and limited sizes and shapes of available grafts. Even if enough tissue is transplanted there is an acute limitation in the number of mesenchymal stem cells with high proliferative potential present in the differentiated bone tissue implanted.

The most promising approach should involve the combined transplantation of cells capable of formation of both hyaline cartilage and subchondral bone and a matrix, providing means for induction/conduction and support of bone and cartilage development and maintenance.

It is widely accepted that, for successful application of combined cell-matrix graft, the basic requirements are the following:

1. Rich source of progenitor cells capable of differentiation into chondrocytes, for continuous repair of "wear and tear" of weight bearing joints.
2. Conductive scaffold for cell attachment should be maintained, leading to development of hyaline cartilage.
3. Conductive scaffold should be non-immunogenic, non-toxic and susceptible to biodegradation simultaneously with the development of new cartilage.

4. Conditions for stimulating development of chondrocytes from mesenchymal precursor cells.

So far, most of the matrices that were tried in combined cell-matrix grafts were either immunogenic or non-biodegradable, and the remaining others did not possess conductive or inductive properties needed to support formation of biomechanical strong cartilage. Cells used in combined cell-matrix grafts were in most of the cases chondrocytes, which were already fully differentiated cells, with relatively low metabolic activity and limited self-renewal capacity. Whereas the proliferative capacity of such cells may be sufficient to maintain healthy cartilage, it is certainly insufficient for the development *de novo* of large areas of hyaline cartilage. In addition to being immunogenic, mesenchymal progenitor cell allografts were not combined with optimal supportive matrix. Thus, unfortunately, none of the available options fulfill all basic requirements, and all options are far from being satisfactory for reliable routine clinical application.

Co-pending International Patent Application PCT/IL02/00172, fully incorporated herein by reference, describes a composition comprising BMC and DBM and/or MBM which provides, upon administration into a damaged joint, replacement and/or restoration of hyaline cartilage together with subchondral bone, in a one-step transplantation procedure, without any preliminary cultivation of mesenchymal progenitor cells. As shown in PCT/IL02/00172, the application of the two components, BMC and DBM together, is both essential and sufficient for the development of new bone and cartilage at the place of the transplantation. This method can be successfully used to initiate and/or improve the efficiency of bone and cartilage formation. It proved to be very effective in (i) repair of damaged osteochondral complex in joints; and (ii) repair or replenishment of the bones in crano-maxillo-facial areas (for therapeutic and cosmetic purposes). The composition induced the development of the new bone and cartilage according to the local conditions of

the site of transplantation. New tissue formation follows a differentiation pathway producing different types of bone and cartilage, depending on the local conditions. Thus, the newly formed tissue meets precisely the local demands.

A major prerequisite for successful replenishment of damaged bone and cartilage structures by transplantation of BMC-DBM composition is the ability to provide for the integrity and stability of shape of the transplant, withstanding mechanical influence during the period of tissue regeneration, whilst maintaining ease of administration.

The administration into a damaged joint or bone of a syringeable usually relatively non-viscous composition, may therefore require keeping the patient at rest and in an unchanging position, until adequate induction of bone and/or cartilage is initiated and obtained, to prevent the composition from migrating and leaving the injection site. In order to improve the procedure, the present inventors have developed an improved composition, which comprises in addition to BMC and DBM, a reverse thermogelating (RTG) polymer, which is liquid, and thus syringeable, at ambient temperature, and gels at body temperature. This composition, which is a major object of the present invention, forms a stable depot at the site of injection, which enables the maintenance of the integrity and stability of shape of the transplant, whilst providing mechanical properties essential to temporarily meet the requirements of the recipient throughout the period of tissue regeneration.

The goals of supplementing the active bone and cartilage regenerating complex consisting of DBM and BMC with additional polymeric materials are therefore:

1. To maintain integrity and shape of the transplanted complex.
2. To provide the transplanted complex with the mechanical properties essential to temporarily meet the requirements of the organism (such as

withstanding physical and mechanical pressure, etc.) throughout the period of tissue regeneration.

The inventors have interestingly found that the addition of biocompatible, biodegradable, reverse thermogelating polymers achieves these objects.

Thus, in order to improve the properties of a BMC-DBM active complex, it may be supplemented with a substance possessing the following features:

1. The supplement has to be compatible with proliferation and differentiation of mesenchymal progenitor cells, in the course of bone and/or cartilage formation.
2. The supplement has to be slowly biodegradable or dissolvable in the body fluids, the degradation time being compatible with the period of *de novo* chondro- and osteogenesis.
3. The supplement has to be non-immunogenic.
4. The supplement has to be provided in a form (state) allowing its mixing with the components of the active complex (DBM and BMC).
5. The supplement after its admixture with the active complex has to render it sufficiently strong to maintain integrity and shape as well as to provide biomechanical properties to the transplant during the period of new tissue formation.

The inventors have now found that these requirements are met when using reverse thermogelating polymer.

Biomaterials are materials which are foreign to the human body and can be used in direct contact with its organs, tissues and fluids. These materials include, among others, polymers, ceramics, biological materials, metals, composite materials and combinations thereof. A major prerequisite of polymeric biomaterials is their syringeability, namely being suitable to be

implanted without requiring a surgical procedure. Injectable polymers combine low viscosity at the injection stage (at room temperature), with a gel or solid consistency developed *in situ*, later on (at body temperature). The syringeability of injectable biopolymers is their most essential advantage, since it allows their introduction into the body using minimally invasive techniques. Furthermore, their low viscosity and substantial flowability at the injection time, enable them to reach and fill spaces, otherwise inaccessible, as well as to achieve enhanced attachment and improved conformability to the tissues at the implantation site. On the other hand, a sharp increase in viscosity is a fundamental requirement for these materials to be able to fulfill any physical or mechanical function. The high viscosities play a critical role also in that the generating syringeable materials, once at the implantation site, can control the rate of release of drugs, or can function as the matrix for cell growth and tissue scaffolding. Clearly, biodegradability is yet another important requirement for some of these materials.

U.S patent 5,939,485 discloses responsive polymer networks exhibiting the property of reversible gelation triggered by a change in diverse environmental stimuli, such as temperature, pH and ionic strength. U.S Patent 6,201,065 discloses thermo-responsive macromers based on cross-linkable polyols, such as PEO-FPO-PEO triblocks, capable of gelling in an aqueous solution, which can be covalently crosslinked to form a gel on a tissue surface *in vivo*. The gels are useful in a variety of medical applications including drug delivery.

The term "thermo-sensitive" refers to the capability of a polymeric system to achieve significant chemical, mechanical or physical changes due to small temperature differentials. In order to avoid open surgical procedure, thermo-responsive materials have to be easily syringeable, combining low viscosity at the injection stage, with a gel or solid consistency developed later on, *in situ*.

The reverse thermo-responsive phenomenon is usually known as Reverse Thermal Gelation (RTG). Water solutions of RTG materials display low viscosity at ambient temperature, and exhibit a sharp viscosity increase as temperature rises within a very narrow temperature range, producing a semi-solid gel once they reach body temperature. There are known several RTG displaying polymers, such as poly(N-isopropyl acrylamide) (PNIPAAm) (e.g. U.S. Pat. No. 5,403,893). Unfortunately, N-isopropylacrylamide is toxic, and moreover poly(N-isopropyl acrylamide) is non-degradable and, in consequence, is not suitable where biodegradability is required.

One of the most important RTG-displaying materials is the family of poly(ethylene oxide)/poly(propylene oxide)/ poly(ethylene oxide) (PEO-PPO-PEO) triblocks, available commercially as PluronicTM (U.S. Pat. No. 4,188,373). By adjusting the concentration of the polymer, the desired liquid-gel transition can be obtained, nevertheless, relatively high concentrations of the triblock (typically above 15-20%) are required. Another known system which is liquid at room temperature, and becomes a semi-solid when warmed to about body temperature, is disclosed in U.S. Pat. No. 5,252,318, and consists of tetrafunctional block polymers of polyoxyethylene and polyoxypropylene condensed with ethylenediamine (commercially available as TetronicTM).

However, for most known RTG polymers, even though they exhibit a significant increase in viscosity when heated up to 37°C, the levels of viscosity attained are not high enough for most clinical applications. Due to this fundamental limitation, these systems display unsatisfactory mechanical properties and unacceptable short residence times at the implantation/injection site. Furthermore, due to these characteristics, these gels have high permeability, a property which renders them unsuitable for drug delivery applications because of the fast drug release kinetics of these gels. Despite their clinical potential, these materials have failed to be used

successfully in the clinic, because of serious performance limitations [Steinleitner *et al.*, *Obstetrics and Gynecology*, 77, 48 (1991); Esposito *et al.*, *Int. J. Pharm.* 142, 9 (1996)].

Biodegradability plays a unique role in a diversity of devices, implants and prostheses. Biodegradable polymers need not be removed from the body and can serve as matrices for the release of bioactive molecules and result in improved healing and tissue regeneration processes. Biodegradable polymers such as polyesters of α -hydroxy acids, like lactic acid or glycolic acid, are used in diverse applications such as bioabsorbable surgical sutures and staples, some orthopedic and dental devices, drug delivery systems and more advanced applications such as the absorbable component of selectively biodegradable vascular grafts, or as temporary scaffold for tissue engineering. Biodegradable polyanhydrides and polyorthoesters, having labile backbone linkages, have also been developed. Polymers which degrade into naturally occurring materials, such as polyaminoacids, have also been synthesized. Degradable polymers formed by copolymerization of lactide, glycolide, and ϵ -caprolactone have been disclosed. Polyester-ethers have been produced by copolymerizing lactide, glycolide or ϵ -caprolactone with polyethers, such as polyethylene glycol ("PEG"), to increase the hydrophilicity and degradation rate.

Unfortunately, the few absorbable polymers clinically available today are stiff, hydrophobic solids, therefore clearly unsuitable for non-invasive surgical procedures, where injectability is a fundamental requirement. The only way to avoid the surgical procedure with these polymers, is to inject them as micro or nanoparticles or capsules, typically containing a drug to be released. As an example, injectable implants comprising calcium phosphate particles in aqueous viscous polymeric gels, were first proposed in U.S. Pat. No. 5,204,382. Even though the ceramic component in these polymers is generally considered to be nontoxic, the use of nonabsorbable particulate material seems to trigger a foreign body response both at the site of implantation as well as at remote

sites, due to the migration of the particles, over time.

Another approach is the *in situ* precipitation technique described in U.S. Patent No. 4,938,763, where a water soluble organic solvent is used, in which the polymer is soluble. Once the system is injected, the organic solvent gradually dissolves in the aqueous biological medium, leaving behind an increasingly concentrated polymer solution, until the polymer precipitates, generating the solid implant *in situ*.

In situ polymerization and/or crosslinking are another important techniques used to generate injectable polymeric systems. For example, U.S. patent No. 5,410,016 describes water soluble low molecular precursors having at least two polymerizable groups, that are syringed into the site and then polymerized and/or crosslinked *in situ* chemically or preferably by exposing the system to UV or visible radiation. Langer *et al.* [*Biomaterials*, 21, 259-265 (2000)] developed injectable polymeric systems based on the percutaneous polymerization of precursors, using UV radiation. An additional approach was disclosed in U.S Patent 5,824,333 based on the injection of hydrophobic bioabsorbable liquid copolymers, suitable for use in soft tissue repair.

Although known RTG polymers like PluronicTM may be used as supplements for the BMC-DBM complex used in the present invention, the inventors have also developed novel RTG polymers, which overcome many of the drawbacks of prior art polymers and techniques. The use of these novel polymers in bone and cartilage induction and rehabilitation is also an object of this invention. These polymers will be described in detail hereafter.

The presently proposed use of RTG polymers would afford substantial advantages, particularly in the field of orthopedics and joint repair.

Thus, it is the major object of the present invention to provide a mixture of bone marrow cells and demineralized bone matrix, together with an RTG polymer, for use as a graft in patients in need of restoration of, *inter alia*, damaged joints and/or cranio-facial-maxillary bones, in a one-step transplantation procedure. This and other objects of the invention will be elaborated on as the description proceeds.

Summary of the Invention

The present invention relates to compositions comprising a mixture of bone marrow cells (BMC) and demineralized bone or tooth matrix (DBM or DTM, respectively), together with a reverse thermogelating (RTG) polymer and to their novel uses in the transplantation of mesenchymal progenitor cells into joints and cranio-facial-maxillary area (when the bone is absent to induce bone formation).

Thus, in a first aspect, the present invention relates to a composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM), together with an RTG polymer.

In a second aspect, said composition comprising BMC and DBM together with an RTG polymer, is intended for use in transplantation of mesenchymal progenitor cells present in the bone marrow into a joint or a cranio-facial-maxillary area of a subject in need, wherein said subject is a mammal, preferably a human.

In a first embodiment, the DBM comprised within the composition of the invention is of vertebrate origin, and may be of human origin.

In a second embodiment, the DBM comprised within the composition of the invention is in powder or particle form. The particle size of the DBM may be

about 50 to 2500 μ . Preferably, said particle size is about 250 to 500 μ . The most preferable particle size will depend on the specific needs of each case. Alternatively, the DBM may be in string form, particularly for reconstruction of tendons, or in or larger particles of DBM or slice form for reconstruction of large bone area. Slices or large particles may be perforated, to allow for better impregnation with mesenchymal stem cells.

In another embodiment, the composition of the invention is for restoring and/or enhancing the formation of a new hyaline cartilage and/or sub-chondral bone structure.

In a further embodiment, the composition of the invention is intended for the treatment of a patient suffering from any one of a hereditary or acquired bone disorder, a hereditary or acquired cartilage disorder, a malignant bone or cartilage disorder, conditions involving bone or cartilage deformities and Paget's disease. Additionally, the invention is also intended for the treatment of a patient in need of any one of correction of complex fractures, bone replacement and formation of new bone in plastic or sexual surgery.

In a yet further embodiment, the composition of the invention may further optionally comprise a pharmaceutically acceptable carrier or diluent, as well as additional active agents.

In another aspect, the present invention relates to a method for transplantation of a mixture comprising BMC with DBM and an RTG polymer, optionally further comprising pharmaceutically acceptable carrier or diluent, into a joint and/or a cranio-facial-maxillary bone area of a subject in need, wherein said method comprises introducing into said joint or bone the composition of the invention.

In a first embodiment of the method of the invention, the mixture is administered by any one of the following procedures injection, minimally invasive arthroscopic procedure, or by surgical arthroplasty into the site of implantation, wherein said method is for support or correction of congenital or acquired abnormalities of the joints, cranio-facial-maxillary bones, orthodontic procedures, bone or articular bone replacement following surgery, trauma or other congenital or acquired abnormalities, and for supporting other musculoskeletal implants, particularly artificial and synthetic implants.

Thus, in a further aspect, the invention relates to a method of treating a damaged or degenerative arthropathy associated with malformation and/or dysfunction of cartilage and/or subchondral bone in a mammal in need of such treatment, comprising administering into an affected joint or bone of said mammal a mixture comprising BMC with DBM, together with an RTG polymer, said mixture optionally further comprising a pharmaceutically acceptable carrier or diluent and/or additional active agents.

In one embodiment, the BMC which are present in the administered mixture are either allogeneic or said mammal's own.

In another embodiment, the DBM present in the administered mixture is in a powder, gel, semi-solid or solid form embedded in or encapsulated in polymeric or biodegradable materials.

In a yet further aspect, the present invention relates to a non-invasive (through injection), minimally invasive (through arthroscopy) or surgical transplantation method for support of implants of joints or other musculoskeletal implants, comprising introducing a graft into a joint or a cranio-facial-maxillary bone area of a subject in need, wherein said graft comprises a mixture of BMC and DBM, together with an RTG polymer.

In an even further aspect, the present invention relates to the use of a composition comprising BMC and DBM, together with an RTG polymer, as a graft of mesenchymal and/or mesenchymal progenitor cells for transplantation/implantation into a mammal, wherein said mammal is preferably a human. The transplantation is to be performed into a joint or into a cranio-facial-maxillary bone area, for the development of new bone and/or cartilage.

Furthermore, the composition used in said transplantation is intended for the treatment of a patient suffering from any one of a hereditary or acquired bone disorder, a hereditary or acquired cartilage disorder, a malignant bone or cartilage disorder, conditions involving bone or cartilage deformities and Paget's disease. In addition, said composition is intended for the treatment of a patient in need of any one of correction of complex fractures, bone replacement and formation of new bone in plastic or sexual surgery.

In one embodiment, the composition used in the invention further comprises an additional active agent.

In another embodiment, the DBM comprised within the composition of the invention is of vertebrate origin, and may be of human origin. Said DBM may preferably be in powder form.

In an additional aspect, the present invention concerns the use of a mixture of BMC with DBM, together with an RTG polymer in the preparation of a graft for the treatment of a bone or cartilage disorder.

Lastly, the present invention provides a kit for performing transplantation into a joint or for reconstruction of cranio-facial-maxillary bone area, long bones, pelvis, spines or for dental support through alveolar bone of maxilla and mandibula augmentation or for creation of an artificial hematopoietic

bone of a mammal of BMC in admixture with DBM and an RTG polymer, wherein said kit comprises:

- (a) DBM in powder or a compacted form (e.g. strings for reconstruction of tendons, or larger particles of DBM for reconstruction of large bone area);
- (b) a reverse thermogelating polymer (RTG);
- (c) a BM aspiration needle;
- (d) an intra-osseous bone drilling burr;
- (e) a needle with a thick lumen for infusion of viscous bone marrow-DBM - RTG polymer mixture;
- (f) a 2-way lumen connector for simultaneous mixing of BMC with DBM and RTG polymer and diluent;
- (g) a medium for maintaining BMC; and optionally
- (h) additional factors stimulating osteogenesis
- (i) cryogenic means for handling and maintaining BMC or BMC together with DBM.

It is to be understood that the RTG polymer solution comprised in the kit of the invention is so adjusted as to be capable of undergoing the desired gelation (transition sol-gel) at a temperature close to 37°, to allow the implantation and formation of the gel *in situ*.

The kit of the invention may optionally further comprise a carrier and/or a diluent for the BMC and DBM and RTG polymer mixture.

Although the compositions of the invention may employ any suitable RTG polymer, like Pluronic F127, F108, etc. which are known polymers, some such polymers are preferred. Particularly preferred are novel polymers which are the subject of co-pending United States Patent Application filed on August 15, 2002), entitled Novel Thermosensitive Block Copolymers for Non-Invasive Surgery, the contents of which are fully incorporated herein by reference.

These specifically designed biodegradable reverse thermo-responsive polymers are advantageous for implantation into the human body, specifically for providing a temporary scaffold for tissue repair, and overcome many of the drawbacks of prior art polymers. These polymers covalently combine hydrophobic and hydrophilic segments. The balance between such segments in the molecule plays a dominant role in achieving the desired reverse thermal gelation (RTG) behavior.

The most preferred compositions of the present invention are tailor-made, by capitalizing on the uniqueness of the Reverse Thermal Gelation phenomenon. The endothermic phase transition taking place, is driven by the entropy gained due to the release of water molecules bound to the hydrophobic groups in the polymer backbone. It is clear, therefore, that, in addition to molecular weight considerations and chain mobility parameters, the balance between hydrophilic and hydrophobic moieties in the molecule, plays a crucial role. Consequently, the properties of different materials were adjusted and balanced by variations of the basic chemistry, composition and molecular weight of the different components.

More specifically, in one of the preferred embodiments, the RTG polymers applicable in the compositions and methods of the present invention are selected from the group consisting of polymers having the general formulae:

- (a) $[-X_n-A-X_n-E-B-E]_m$ defined herein as formula Ia;
- (b) $[-X_n-B-X_n-E-A-E]_m$ defined herein as formula Ib;
- (c) $M-X_n-E-B-E-X_n-M$ defined herein as formula IIa;
- (d) $N-X_n-E-A-E-X_n-N$ defined herein as formula IIb;
- (e) $[-X_n-A(X_n)_y(E)_y(B)_y-X_n-E-B-E]_m$ defined herein as formula IIIa;
- (f) $[-X_n-B(X_n)_y(E)_y(A)_y-X_n-E-A-E]_m$ defined herein as formula IIIb;

wherein A represents a bifunctional, trifunctional or multifunctional hydrophilic segment; M represents a monofunctional hydrophilic segment; B

represents a bifunctional, trifunctional or multifunctional hydrophobic segment; N represents a monofunctional hydrophobic segment; X represents a bifunctional degradable segment; E represents bi, tri or multifunctional chain extender or coupler; n and m represent the respective degree of polymerization and y designates the additional functionality of the corresponding segment (wherein $y > 2$).

In a particularly preferred embodiment, A is presented by polyoxyethylene or polyethylene glycol (PEG) units ($O-CH_2-CH_2)_y$ [y represents degree of polymerization] carrying functional groups such as -OH, -SH, -COOH, -NH₂, -CN or -NCO groups. Consequently, A may represent poly(oxyethylene triol), poly(oxyethylene triamine), poly(oxyethylene triacrylic acid), ethoxylated trimethylolpropane, or any other multifunctional hydrophilic segment.

In a particularly preferred embodiment, B is presented by polyoxyalkylene (wherein the alkylene containing more than two C atoms), such as, for example, poly(propylene glycol) (PPG) units [- $O-CH(CH_3)-CH_2$]_y [wherein y represents degree of polymerization] carrying functional groups such as -OH, -SH, -COOH, -NH₂, -CN or -NCO groups. Consequently, B may represent polyoxypropylene diamine (Jeffamine.TM), polytetramethylene glycol (PTMG), polyesters selected from the group consisting of poly(caprolactone), poly(lactic acid), poly(glycolic acid) or combinations or copolymers thereof, polyamides or polyanhydrides or any other bifunctional hydrophobic segment having the appropriate functional group. Trifunctional hydrophobic segment may be selected from the group consisting of poly(oxypropylene triol), poly(oxypropylene triamine), poly(oxypropylene triacrylic acid), or any other trifunctional hydrophobic segment.

E is preferably a chain extender or coupling segment derived from a bifunctional reactive molecule, preferably selected from the group consisting

of phosgene, aliphatic or aromatic dicarboxylic acids or their reactive derivatives, such as oxalyl chloride, malonyl chloride, succinyl chloride, glutaryl chloride, fumaryl chloride, adipoyl chloride, suberoyl chloride, pimeloyl chloride, sebacoyl chloride, terephthaloyl chloride, isophthaloyl chloride, phthaloyl chloride and/or mixtures thereof. E may be further presented by amino acids, such as for example, glycine, alanine, valine, phenylalanine, leucine, isoleucine etc.; oligopeptides, such as RGD (Arg-Gly-Asp), RGD(S) (Arg-Gly-Asp(-Ser)), aliphatic or aromatic diamines such as, for example, ethylene diamine, propylene diamine, butylene diamine, etc.; aliphatic or aromatic diols, such as ethylene diol, propanediol, butylenediol, etc.; aliphatic or aromatic diisocyanates, for example, hexamethylene diisocyanate, methylene bisphenyldiisocyanate, methylene biscyclohexane-diisocyanate, tolylene diisocyanate or isophorone diisocyanate. Trifunctional reactive molecules may be cyanuric chloride, triisocyanates, triamines, triols, trifunctional aminoacids, such as lysine, serine, threonine, methionine, asparagine, glutamate, glutamine, histidine, or oligopeptides. E may also comprise combinations of the functional groups described above in the same molecule. The reaction products are poly(ether-carbonate)s, poly(ether-ester)s, poly(ether-urethane)s or derivatives of chlorotriazine, most preferably poly(ether-carbonate)s, poly(ether-ester)s or poly(ether-urethanes), polyimides, polyureas and combinations thereof.

In a preferred embodiment, M is presented by a monomethyl ether of hydrophilic polyoxyethylene or polyethylene glycol (PEG) units $(O-CH_2-CH_2)_y-OCH_3$ [wherein y represents a degree of polymerization] carrying functional groups such as -OH, -SH, -COOH, -NH₂, -CN or -NCO groups.

In a preferred embodiment N is presented by a monomethyl ether of hydrophobic poly(propylene glycol) (PPG) units $[-O-CH(CH_3)-CH_2]_y-OCH_3$ [wherein y represents degree of polymerization] carrying functional groups such as -OH, -SH, -COOH, -NH₂, -CN or -NCO groups.

Preferred biodegradable X segments in the RTG polymers applicable in the compositions and methods of present invention possess hydrolytic instability and they are characterized by being aliphatic or aromatic esters, amides and their anhydride derivatives formed from alpha-hydroxy carboxylic acid units or their respective lactones.

According to the present invention, the most preferred polymers to be employed comprise amphiphiles obtained by the combination of both hydrophobic and hydrophilic basic segments, which, separately, do not display any kind of clinically relevant viscosity change of their own, and are capable of undergoing a transition that results in a sharp increase in viscosity in response to a triggering effected at a predetermined body site and an aqueous-based solvent wherein the viscosity of said polymeric component increases by at least about 2 times upon exposure to a predetermined trigger.

More specifically, the most preferred polymers used in this invention capable of undergoing a transition that results in a sharp increase in viscosity in response to a change in temperature at a predetermined body site; wherein the polymeric component comprises hydrophilic and hydrophobic segments covalently bound within said polymer component, by at least one chain extender or coupling agent, having at least 2 functional groups; wherein the hydrophilic and hydrophobic segments do not display Reverse Thermal Gelation behavior of their own at clinically relevant temperatures and; wherein the viscosity of said polymeric component increases by at least about 2 times upon exposure to a predetermined trigger.

In further preferred embodiments of the present invention said responsive component is a segmented block copolymer comprising polyethylene oxide (PEO) and polypropylene oxide (PPO) chains, wherein said PEO and PPO chains are connected via a chain extender, wherein said chain extender is a bifunctional, trifunctional or multifunctional molecule selected from a group

consisting of phosgene, aliphatic or aromatic dicarboxylic acids, their reactive derivatives such as acyl chlorides and anhydrides, diamines, diols, aminoacids, oligopeptides, polypeptides, or cyanuric chloride or any other bifunctional, trifunctional or multifunctional coupling agent, or other molecules, synthetic or of biological origin, able to react with the mono, bi, tri or multifunctional -OH, -SH, -COOH, -NH₂, -CN or -NCO group terminated hydrophobic and hydrophilic components or any other bifunctional or multifunctional segment, and/or combinations thereof.

Brief Description of the Figures

Figure 1: Photomicrographs of mice kidney sections after subcapsular transplantation of demineralized tooth matrix and bone marrow cells with or without different RTG polymers (Picroindigocarmine staining).

One month post-transplantation of BMC+DBM together with RTG polymers (NN 2, 4, 7) newly formed cortical and trabecular bone, well developed marrow cavity and functionally active bone marrow are seen. No difference in the developmental level of the ectopic ossicles produced by DTM-BMC complex transplanted with or without RTG polymers could be observed.

BMC transplanted without DBM but supplemented with one of the mentioned RTG polymers produced in most of the cases a small ossicles. It means that RTG polymers successfully keep transplanted BMC together and prevent their migration out of the transplantation site.

Implantation of mentioned RTG polymers alone under the kidney capsule never left any trace in the site of transplantation – neither bone formation nor any side effects such as inflammation etc.

Figure 2: Photomacro- and micrographs illustrating the experimental models of artificially created defects in osteochondral complex of

knee joint and parietal region of calvarium in rats.
(Picroindigocarmine staining).

Fig. 2A shows a typical knee joint, Fig. 2B shows the osteochondral complex, and Fig. 2C shows normal cartilage. A standard artificial damage (experimentally created microfracture drilling) in the articular cartilage and subchondral bone in the intracondillar region of femoral bone immediately after its creation is shown in Fig. 2D (x5).

Fig. 2E shows normal rat cranium. Defect area in parietal bone immediately after removal of 6x6 mm² full thickness bone segment is shown on Macro (Fig. 2F) and X-Ray (Fig. 2G) pictures. Microsection through the defect area is presented in Fig. 2H (x5).

Abbreviations: NC, normal cartilage; DA., defect area;

Figure 3: Influence of RTG polymers (N2 and N4) on correction of experimentally created calvarial defect by transplantation of demineralized bone matrix (DBM) and bone marrow cells (BMC). Sagittal sections stained with Picroindigocarmine.

X-Ray and Macro pictures of rats calvaria one month after transplantation of DBM-BMC complex supplemented with RTG – polymeric materials N2 and N4 into the area of experimentally created calvarial defect show complete regeneration of the bone.

Photomicrograph (x10) of cranial sections 30 days after the experimentally created calvarial defect followed by transplantation of DBM-BMC complex supplemented with RTG – polymeric materials N2 and N4 show continuous layer of newly developed bone tissue with hematopoietic areas and active remodeling of the transplanted DBM particles. Cut edge of the bone can hardly be seen.

Abbreviations: D A., defect area; CE., cut edge;

Figure 4: Influence of RTG polymer N7 on correction of experimentally created calvarial defect by transplantation of

demineralized bone matrix (DBM) and bone marrow cells (BMC).

Sagital sections stained with Picroindigocarmine.

X-Ray and Macro pictures of rats calvaria one month after transplantation of DBM-BMC complex supplemented with RTG – polymeric material N7 into the area of experimentally created calvarial defect show complete regeneration of the bone.

Photomicrograph (x10) of cranial sections 30 days after the experimentally created calvarial defect followed by transplantation of DBM-BMC complex supplemented with RTG – polymeric material N7 show continuous layer of newly developed bone tissue with hematopoietic areas and active remodeling of the transplanted DBM particles.

Abbreviations: D A., defect area; CE., cut edge;

Figure 5: Influence of different RTG polymers on correction of experimentally created calvarial defect by transplantation of bone marrow cells (BMC). Sagital sections stained with Picroindigocarmine.

X-Ray and Macro pictures of rats calvaria one month after transplantation of BMC supplemented only with RTG – polymeric materials into the area of experimentally created calvarial defect show absence of bone regeneration.

Photomicrograph (x10) of cranial sections 30 days after the experimentally created calvarial defect followed by transplantation of BMC supplemented only with RTG – polymeric materials confirms the absence of new bone development

Abbreviations: D A., defect area; CE., cut edge;

Figure 6: Photomicrographs of sagital knee joint sections one month after the experimentally created microfracture drilling defect followed by transplantation of demineralized bone matrix and bone marrow cells with RTG polymers N2 and N4 (Picroindigocarmine staining).

Figs. 6 A&B: Mixture of DBM particles with BMC supplemented with RTG polymer N2 was transplanted into defect area (x10 & x20). Active angiogenesis as well as partial degradation and remodeling of DBM particles are seen. No cartilage development can be observed, regenerating surface is built of connective tissue.

Figs. 6 C&D: BMC supplemented with RTG polymer N2 were transplanted into defect area (x10 & x20). Regeneration of subchondral bone and hematopoietic cavities, no cartilage formation, regenerating surface is built of connective tissue.

Figs. 6 E&F: Mixture of DBM particles with BMC supplemented with RTG polymer N4 was transplanted into defect area (x10 & x20). Partial degradation and remodeling of DBM particles are seen as well as development of hematopoietic cavities. No chondrogenesis can be seen; regenerating surface is built of connective tissue.

Figs. 6 G&H: BMC supplemented with RTG polymer N4 were transplanted into defect area (x10 & x20). Regeneration of subchondral bone and hematopoiesis; no cartilage formation, regenerating surface is built of connective tissue.

Figure 7: Photomicrographs of sagital knee joint sections 4 weeks after the experimentally created microfracture drilling defect followed by transplantation of demineralized bone matrix and bone marrow cells with RTG polymer N7 (Picroindigocarmine staining).

Figs. 7A&B: Mixture of DBM particles with BMC supplemented with RTG polymer N7 was transplanted into defect area (x10 & x20). Extensively developing hyaline cartilage, as well as considerably degraded DBM particles can be seen. Regenerating surface is built of thick layer of hyaline cartilage.

Figs. 7C&D: BMC supplemented with RTG polymer N7 were transplanted into defect area (x10 & x20). Complete regeneration of subchondral bone; surface of the damaged area comprises a mixture of connective tissue with cartilage cells.

Figure 8: Photomicrographs of sagital knee joint sections two months after the experimentally created microfracture drilling defect followed by transplantation of demineralized bone matrix and bone marrow cells with RTG polymers N2 and N4 (Picroindigocarmine staining).

Figs. 8 A&B: Mixture of DBM particles with BMC supplemented with RTG polymer N2 was transplanted into defect area (x10 & x20). Complete regeneration of subchondral bone is seen. No cartilage development can be observed, regenerating surface is built of connective tissue.

Figs. 8 C&D: BMC supplemented with RTG polymer N2 were transplanted into defect area (x10 & x20). Regeneration of subchondral bone and hematopoietic cavities, no cartilage formation, regenerating surface is built of connective tissue.

Figs. 8 E&F: Mixture of DBM particles with BMC supplemented with RTG polymer N4 was transplanted into defect area (x10 & x20). Almost degraded DBM particles and well developed subchondral bone and hematopoietic cavities are seen. No chondrogenesis, regenerating surface is built of connective tissue.

Figs. 8 G&H: BMC supplemented with RTG polymer N4 were transplanted into defect area (x10 & x20). Regeneration of subchondral bone and hematopoiesis; no cartilage formation, regenerating surface is built of connective tissue.

Figure 9: Photomicrographs of sagital knee joint sections two months after the experimentally created microfracture drilling defect followed by transplantation of demineralized bone matrix and bone marrow cells with RTG polymer N7 (Picroindigocarmine staining).

Figs. 9A&B: Mixture of DBM particles with BMC supplemented with RTG polymer N7 was transplanted into defect area (x10 & x20). Continuous layer

of young hyaline cartilage, as well as complete regeneration of subchondral bone can be seen, considerably degraded DBM particles are yet present.

Figs. 9C&D: BMC supplemented with RTG polymer N7 were transplanted into defect area (x10 & x20). Complete regeneration of subchondral bone; surface of the damaged area comprises a mixture of connective tissue with cartilage cells.

Figure 10: Photomicrographs of sagital knee joint sections one month after the experimentally created microfracture drilling defect followed by transplantation of demineralized bone matrix and bone marrow cells without the addition of polymeric materials. (Picroindigocarmin staining).

The Figure illustrates cases of incomplete repair of damaged osteochondral complex in the rat knee joint when the active composition comprising of DBM and BMC was applied alone without sufficient fixation with polymeric materials.

Fig.10 A. Most of BMC were washed out of the site of transplantation. Thus the transplanted area is packed with non-remodeled DBM particles; almost no new bone formation is observed.

Fig.10 B. Partial regeneration of subchondral bone, and surface hyaline cartilage, however some of DBM particles thrust into the joint surface preventing the formation of continuous cartilage layer.

Fig.10 C. Total regeneration of subchondral bone and hematopoiesis, however the surface is occupied by DBM.

Fig.10 D. The active composition comprising of DBM and BMC was washed out of the damaged area, as a result, regenerating site is mostly filled by connective tissue.

Detailed Description of the Invention

The following abbreviations are utilized throughout this specification:

- BM: bone marrow.
- BMC: bone marrow cell(s).
- BMP: bone morphogenetic protein.
- DBM: demineralized bone matrix.
- DTM: demineralized tooth matrix (DBM and DTM are used herein interchangingly).
- LCM: Laser Capture Microdissection.
- MBM: mineralized bone matrix.
- PCR: polymerase chain reaction.
- PIC: Picroindigocarmine, a dye used in histological staining.
- RTG: Reverse thermogelating (polymer).

In search for improving the regeneration of damaged osteochondral complex in joint and crano-facial-maxillary areas, by using a composition comprising BMC and DBM as a graft, the inventors have found that the addition of a highly viscous polymer to a composition comprising BMC and DBM results in the formation of a depot at the site of injection, preventing the migration of the BMC and DBM mixture away from the transplantation site. Moreover, the inventors have now interestingly proposed the use of not just a highly viscous polymer, which may not be syringeable at ambient temperatures, but to use an RTG polymer, which is liquid and thus injectable at ambient temperature, yet gels at body temperature, forming the desired depot, which enables the maintenance of the integrity and stability of shape of the transplant, whilst providing mechanical properties essential to temporarily meet the requirements of the recipient throughout the period of tissue regeneration. The term body temperature as used herein is to be taken to mean a temperature of between 35°C and 42°C, preferably about 37°C, particularly 37°C. The addition of the RTG polymer did not adversely affect the new tissue formation which follows a differentiation pathway producing different types of bone and cartilage, depending on the local conditions. Thus, the newly formed tissue meets precisely the local demands.

The present invention relates to compositions comprising a mixture of bone marrow cells (BMC) and demineralized bone matrix (DBM) and an RTG polymer, and to their novel uses in the transplantation of mesenchymal progenitor cells into joints and crano-facial-maxillary bones.

Thus, in a first aspect, the present invention relates to a composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and a biocompatible, biodegradable RTG polymer.

DBM is an essential ingredient in the composition of the invention in view of its advantageous ability to combine all the features needed for making it an excellent carrier for mesenchymal progenitor cells. The properties of DBM can be summarized as follows:

1. DBM can be a conductive scaffold essential for the engraftment, proliferation and differentiation of mesenchymal progenitor cells, in the course of bone and cartilage formation.
2. DBM is the natural source of BMPs, which are active in stimulating osteo- and chondrogenesis, thus also fulfilling the inductive function.
3. DBM is slowly biodegradable, the degradation time being compatible with the period of *de novo* chondro- and osteogenesis.
4. DBM has very low immunogenicity when used as a xenograft, and it is practically non-immunogenic when used in allogeneic combinations.
5. DBM can be provided as an amorphous powder that can be injected locally, without major surgical intervention, thus avoiding iatrogenic damage in the site of transplantation.

The properties of RTG polymers can be summarized as follows:

1. Excellent compatibility with proliferation and differentiation of mesenchymal progenitor cells, in the course of bone and cartilage formation.

2. Slow solubility in body fluids, with the time being compatible with the period of *de novo* chondro- and osteogenesis.
3. Total absence of immunogenicity.
4. Liquid form at room temperature, allowing mixing it with the components of the active complex (DBM and BMC).
5. Ability to develop high viscosity at body temperature.

After its admixture with the active complex, the RTG supplement is capable of rendering the complex sufficiently strong to maintain integrity and shape as well as to provide biomechanical properties to transplant, withstanding mechanical forces, during the period of new tissue formation. In this view it must be better to remove point 5 from "The properties of DBM" page 27.

In a second aspect, said composition comprising BMC and DBM and the RTG polymer is for use in transplantation of mesenchymal cells and/or mesenchymal progenitor cells into a joint and/or a crano-facial-maxillary area of a subject in need, wherein said subject is a mammal, preferably a human.

It is an object of the present invention to provide the said composition for transplantation of BMC into damaged joints and/or a crano-facial-maxillary area for the replacement and/or restoration of hyaline cartilage and bone, originating from the mesenchymal precursor cells existing in the transplanted BMC.

The DBM comprised within the composition of the invention is preferably of vertebrate origin, and may be of human origin.

The DBM comprised within the composition of the invention is preferably in powder form. The particle size of the DBM may be about 50 to 2500 μ . Preferably, said particle size is about 250 to 500 μ . The most preferable particle size will depend on the specific needs of each case.

In another embodiment, the composition of the invention is for restoring and/or enhancing the formation of a new hyaline cartilage and bone structure.

As described in PCT/IL02/00172, the idea underlying the administration of a mixture of DBM with BMC is that BMC may provide a source for mesenchymal stem cells, which are capable of inducing osteo- and chondrogenesis. Thus, as described in said application, when a BMC suspension in admixture with DBM powder was administered directly into either a joint bearing a damage in the osteo-chondral complex, or in the cranium of an animal with a partial bone defect in the parietal bone, significant restoration occurred.

The idea underlying the present invention is that supplementing the active composition of BMC and DBM with polymeric materials exhibiting high viscosity at body temperature, results in improving the ability to maintain the integrity and shape of the transplanted complex, whilst providing mechanical properties essential to temporarily meet the requirements of the organism (such as withstanding physical pressures etc) throughout the period of tissue regeneration.

Thus, as described in the following examples, when a mixture of BMC suspension and DBM powder, in admixture with RTG polymeric materials was administered directly into either a joint damaged in the osteo-chondral complex, or in the cranium of an animal with a critical size bone defect, significant restoration occurred. Treated recipients were mobile with no need for fixation of the joints, and full restoration of the anatomic structure of the treated joint was accomplished. This is a major advantage of the compositions of the present invention, since it obviates the need for long periods of rest following transplantation/implantation. Likewise, newly reconstituted parietal bone replacing surgically removed parietal bone in the skull showed normal

remodeling. In the damaged joint, there was formation of subchondral bone structure and hyaline cartilage, and in the cranial defect, new flat bone was formed.

The present compositions obviate the need for using biological say fixation and/or strengthening, necessary in the application of the earlier BMC-DBM complexes. In addition, the present compositions provide a scaffold and template for molding any desirable shape and structure, according to the location of the implant. Such a scaffold provides an immediate mechanical support that minimizes the need for immobilization of the recipient following therapy. In addition the feasibility of injection of the mixture into the joint, may avoid the need for open surgery, thus minimizing iatrogenic damage, discomfort, need for immobilization, scar formation and risk of infections.

In a further embodiment, the composition of the invention is intended for the treatment of a patient suffering from any one of a hereditary or acquired bone disorder, a hereditary or acquired cartilage disorder, a malignant bone or cartilage disorder, metabolic bone diseases, bone infections, conditions involving bone or cartilage deformities and Paget's disease. Said disorders are listed in detail in Table 1. Additionally, the invention is also intended for the treatment of a patient in need of any one of correction of complex fractures, bone replacement, treatment of damaged or degenerative arthropathy and formation of new bone in plastic or sexual surgery.

Table 1

Congenital and Hereditary Bone Disorders	Bone Infections	Metabolic Bone Diseases	Non-neoplastic Disorders of the Bone
Achondroplasia	Hematogenous (Pyogenic) Osteomyelitis	Osteoporosis	Fibrous Dysplasia of the Bone
Osteogenesis Imperfecta (Brittle Bones, Fragilitas Ossium)	Osteomyelitis from Contiguous Infection	Rickets and Osteomalacia	Fibrous Cortical Defect and Non-ossifying Fibroma
Osteopetrosis (Marble Bone Disease, Osteosclerosis)	Osteomyelitis from an Introduced Infection	Bone Changes in Hyperparathyroidism (Generalized Osteitis, Cystic Fibrosis, Von Recklinghausen's Bone Disease)	Solitary Bone Cyst (Unicameral Bone Cyst)
Hereditary Multiple Exostosis (Osteochondromatosis)	Bone Tuberculosis	Renal Osteodystrophy	Aneurysmal Bone Cyst
Enchondromatosis (Ollier's Disease)	Bone Syphilis	Paget's Disease of Bone (Osteitis Deformans)	Eosinophilic Granuloma of Bone
	Bone Fungus Infections		Bone Lesions of Gaucher's Disease

14729/WO/01

33

In a yet further embodiment, the composition of the invention may further optionally comprise a pharmaceutically acceptable carrier or diluent, as well as additional active agents.

Pharmaceutically acceptable (or physiologically acceptable) additive, carrier and/or diluent mean any additive, carrier or diluent that is non-therapeutic and non-toxic to recipients at the dosages and concentrations employed, and that does not affect the pharmacological or physiological activity of the active agent.

The preparation of pharmaceutical compositions is well known in the art and has been described in many articles and textbooks, see e.g., Remington's Pharmaceutical Sciences, Gennaro A. R. ed., Mack Publishing Company, Easton, Pennsylvania, 1990, and especially pages 1521 -1712 therein.

Active agents of particular interest are those agents that promote tissue growth or infiltration, such as growth factors. One example is BMPs, which may enhance the activity of the composition of the invention. Other exemplary growth factors for this purpose include epidermal growth factor (EGF), osteogenic growth peptide (OGP), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factors (TGFs), parathyroid hormone (PTH), leukemia inhibitory factor (LIF), insulin-like growth factors (IGFs), and growth hormone. Other agents that can promote bone growth, such as the above-mentioned BMPs, osteogenin [Sampath *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:7109-13] and NaF [Tencer *et al.* (1989) *J. Biomed. Mat. Res.* 23: 571-89] are also preferred.

Other active agents may be anti-rejection or tolerance inducing agents, as for example immunosuppressive or immunomodulatory drugs, which can be important for the success of bone marrow allografts or xenografts transplantation.

Alternatively, said active agents may be for example antibiotics, provided to treat and/or prevent infections at the site of the graft. On the same token, anti-inflammatory drugs can also be added to the composition of the invention, to treat and/or prevent inflammations at the site of the graft. Said inflammations could be the result of for example rheumatoid arthritis, or other conditions.

In addition to the RTG, the compositions of the invention may contain other polymeric or biodegradable materials, which are pharmaceutically acceptable carriers and diluents. Biodegradable films or matrices, semi-solid gels or scaffolds include calcium sulfate, tricalcium phosphate, hydroxyapatite, polylactic acid, polyanhydrides, bone or dermal collagen, fibrin clots and other biologic glues, pure proteins, extracellular matrix components and combinations thereof. Such biodegradable materials may be used in combination with non-biodegradable materials, to provide additional desired mechanical, cosmetic or tissue or matrix interface properties.

In preferred embodiments, the composition of the invention contains BMC-DBM mixture and polymeric material at a ratio of from 5:1 to 1:5, preferably between 3:1-and 1:2, most preferably at a ratio of 2 part BMC-DBM mixture to 1 part of polymeric material in fluid form (volume:volume). The absolute number of BMC, as well as the volumes of DBM and polymeric material are dependent on the size of the joint to be rehabilitated or the size (surface, shape and thickness) of the bone to be replaced, while the cell concentrations of BMC suspensions ranging from $1 \times 10^6/\text{ml}$ to $1 \times 10^8/\text{ml}$ and DBM at a ratio of from 1:1 to 20:1, preferably between 2:1 to 9:1, most preferably the composition of the invention is at a ratio of 4 parts BMC concentrate to 1 part of DBM in powder form (volume:volume).

In order to obtain the desired viscosity following injection, the concentration of the polymer in the compositions of the invention is to be carefully adjusted. The optimal concentration will be achieved using Viscosity vs. Concentration calibration curves. The results presented herein show that the concentration of the polymer is to be optimized, and generally, very high concentration are to be avoided, because they may prevent the desired flow of biological nutrients and molecules and thus adversely affect the induction process.

In another aspect, the present invention relates to a method for transplantation of a mixture comprising BMC with DBM and an RTG polymer, optionally further comprising pharmaceutically acceptable carrier or diluent, into a joint and/or a crano-facial-maxillary bone area of a subject in need, wherein said method comprises introducing into said joint or bone the composition of the invention.

The composition of the invention, which possesses all the essential features for accomplishing local bone formation wherever it is implanted, can be efficiently applied for all kinds of bone repair or substitution, especially in places lacking or deprived of mesenchymal stem cells. Amongst the most problematic places in this sense are joints, crano-facial-maxillary areas and different kinds of segmental bony defects. Thus, the present invention may be explained as a complex graft, comprising all necessary components, and which its implantation into a damaged area is sufficient for regeneration or substitution of removed, damaged or destroyed cartilage and/or bone.

In a first embodiment of the method of the invention, the mixture is administered by any one of the following procedures, injection, minimally invasive arthroscopic procedure, or by surgical arthroplasty into the site of implantation, wherein said method is for support or correction of congenital or acquired abnormalities of the joints, crano-facial-maxillary bones, orthodontic procedures, bone or articular bone replacement following surgery, trauma or

14729/WO/01

36

other congenital or acquired abnormalities, and for supporting other musculoskeletal implants, particularly artificial and synthetic implants.

Thus, in a further aspect, the invention relates to a method of treating a damaged or degenerative arthropathy associated with malformation and/or dysfunction of cartilage and/or subchondral bone in a mammal in need of such treatment, comprising administering into an affected joint or bone of said mammal a mixture comprising BMC with DBM, together with an RTG polymer, said mixture optionally further comprising a pharmaceutically acceptable carrier or diluent and/or additional active agents.

As demonstrated in the following examples, the addition of the RTG polymer did not adversely affect the process of induced development (i.e. proliferation and differentiation) of mesenchymal progenitor cells present within the BMC/DBM(DTM)/RTG mixture can accomplish bone and cartilage formation wherever the mixture is transferred to. The findings presented herein indicate that administration of the composition of the invention into a damaged area of the joint, results in generation of new osteochondral complex consisting of articular cartilage and subchondral bone, same as in the absence of the RTG. When administered into an experimentally created calvarial defect, the composition of the invention results in generation of full intramembranous bone development at the site of transplantation. New tissue formation follows a differentiation pathway, producing different types of bone and cartilage, depending on the local conditions. Thus, the newly formed tissue meets precisely the local demands.

The procedure of applying the composition of the invention into a damaged joint or cranial area comprises the following steps:

1. Selecting the source for BMC. The donor may be allogeneic or the BMC may be obtained from the same treated subject (autologous transplantation).

14729/WO/01

2. Selecting the source of DBM. The DBM may be supplied commercially and since it is not immunogenic, there are no limitations for a specific donor. DBM may be in powder, granules or in slice form. The particle size of the DBM may be about 50 to 2500 μ . Preferably, said particle size is about 250 to 500 μ . The most preferable particle size will depend on the specific needs of each case.

3. Preparing a composition comprising a suspension of BMC, at a cell concentration ranging from 1×10^6 /ml to 4×10^{10} /ml and mixing it with DBM at a ratio of from 1:1 to 20:1, preferably between 2:1 to 9:1, most preferably the composition of the invention is at a ratio of 4 parts BMC concentrate to 1 part of DBM in powder form (volume:volume). MBM may be used instead of DBM. If so desired, BMP may optionally be included in the composition.

4. Adding to the composition obtained in step 3 a RTG polymer, at an optimal concentration for the RTG polymer used.

5. Administering the composition obtained in step 4 into a subject in need either through a syringe (non-invasive injection), closed arthroscopy or open surgical procedure. Alternatively, the composition may be administered so that it is encapsulated within normal tissue membranes. Still alternatively, the composition may be contained within a membranous device made of a selective biocompatible membrane that allows cells, nutrients, cytokines and the like to penetrate the device, and at the same time retains the DBM articles within the device. Such a membranous device, bone strips or additional scaffolds are preferably surgically introduced.

In a yet further aspect, the present invention relates to a non-invasive transplantation method comprising introducing a graft into a joint or a cranio-facial-maxillary bone of a subject in need, wherein said graft comprises a mixture of BMC and DBM together with an RTG polymer.

In the examples presented herein (see Examples), the inventors show that administration of the composition of the present invention (e.g. BMC in

admixture with DBM and an RTG polymer, as in Example 3) into a damaged area of the joint is essential and sufficient for the generation of new osteochondral complex, consisting of articular cartilage and subchondral bone, at the site of transplantation. The newly formed donor-derived osteochondral complex was capable of long-term maintenance, remodeling and self-renewal, as well as carrying out specific functions of joint surface, such as motion and weight bearing.

In an even further aspect, the present invention relates to the use of a composition comprising BMC and DBM together with an RTG polymer as a graft of mesenchymal and/or mesenchymal progenitor cells for transplantation into a mammal, wherein said mammal is preferably a human. The transplantation is to be performed into a joint or into a cranio-facial-maxillary bone, for the development of new bone and/or cartilage. The graft of said transplantation may also be for supporting orthodontic procedures for bone augmentation caused by aging, or by congenital, acquired or degenerative processes.

Furthermore, the composition used in said transplantation is intended for the treatment of a patient suffering from any one of a hereditary or acquired bone disorder, a hereditary or acquired cartilage disorder, a malignant bone or cartilage disorder, conditions involving bone or cartilage deformities and Paget's disease. In addition, said composition is intended for the treatment of a patient in need of any one of correction of complex fractures, bone replacement, treatment of damaged or degenerative arthropathy and formation of new bone in plastic or sexual surgery.

The method of the invention may also be used to induce or improve the efficiency of bone regeneration in damaged cranio-facial-maxillary areas, for therapeutic and cosmetic purposes.

14729/WO/01

In one embodiment, the composition used in the invention further comprises an additional active agent.

In another embodiment, the DBM comprised within the composition used in the invention are of vertebrate origin, and they may be of human origin. Moreover, said DBM is preferably in powder form.

In an additional aspect, the present invention concerns the use of a mixture of BMC with DBM together with an RTG polymer in the preparation of a graft for the treatment of a bone or cartilage disorder, and/or for support of musculoskeletal implants, as a scaffold to enforce metal implants, joints, etc. that may become loose with time, or to provide a continuously adapting "biological scaffold" to support such non-biological implants. Alternatively, the invention could be for the support of limb transplants, especially in the articular/bone junction.

Lastly, the present invention provides a kit for performing transplantation into a joint or for reconstruction of cranio-facial-maxillary bone area, long bones, pelvis, spines or for dental support through alveolar bone of maxilla and mandibula augmentation or for creation of an artificial hematopoietic bone of a mammal of BMC in admixture with DBM and an RTG polymer, wherein said kit comprises:

- (a) DBM in powder or a compacted form (e.g. strings for reconstruction of tendons, or larger particles of DBM for reconstruction of large bone area);
- (b) a reverse thermogelating polymer (RTG);
- (c) a BM aspiration needle;
- (d) an intra-osseous bone drilling burr;
- (e) a needle with a thick lumen for infusion of viscous bone marrow-DBM - RTG polymer mixture;
- (f) a 2-way lumen connector for simultaneous mixing of BMC with DBM and RTG polymer and diluent;

14729/WO/01

40

- (g) a medium for maintaining BMC; and optionally
- (h) additional factors stimulating osteogenesis
- (i) cryogenic means for handling and maintaining BMC or BMC together with DBM.

The kit of the invention may optionally further comprise a carrier and/or a diluent for the BMC and DBM mixture, and for the RTG polymer.

The present inventors have previously concluded (as in PCT/IL02/00172) that transplantation of multipotent mesenchymal stem cells, and not of differentiated bone or chondrocytes, for remodeling and restoration of a healthy joint or crano-facial-maxillary structure in arthropathy, is especially important for the following reasons:

- (1) Chondrocytes, as well as the cells transferred within a bone transplant are already fully differentiated cells, with relatively low metabolic activity and limited self-renewal capacity that may be sufficient to maintain healthy cartilage or bone, but is certainly insufficient for the development of large areas of bone or of hyaline cartilage *de novo*.
- (2) Most frequently in joints, both cartilage and subchondral bone are damaged. Thus, even a successfully developed new hyaline cartilage is unlikely to be maintained for long if the subchondral bone is left damaged. Based on these findings, it was observed in the following examples that mesenchymal stem cells present in bone marrow, if transplanted under the appropriate conditions, will create a self-supporting osteochondral complex providing healthy joint surface.

It is not yet clear what makes multipotential mesenchymal stem cells, under the influence of DBM, to choose between an osteogenic and a chondrogenic differentiation pathway. It has however been reported that the ratio of cartilage to bone production depends in particular on the site of DBM implantation, which is naturally influenced by the local conditions [Inoue, T.

14729/WO/01

41

et al. (1986) *J Dent Res* 65(1):12-22], such as the local source of mesenchymal cells and blood supply [Reddi, A.H. and Huggins, C.H. (1973) *P.S.E.B.M.* 143:634-637]. Low oxygen tension favors chondrogenesis [Bassett, C.A.L. (1962) *J Bone Joint Surg* 44A:1217], most likely due to the low O₂ tension in poorly vascularized cartilage [Sledge, C.B. and Dingle, J.T. (1965) *Nature (London)* 205: 140]. Interestingly, a successful substitution of anterior cruciate ligament (ACL) by demineralized cortical bone matrix has been reported in a goat model [Jackson, D.W. *et al.* (1996) *Amer J Sports Medicine* 24(4):405-414]. The remodeling process included new bone formation within the matrix in the osseous tunnels and a ligament-like transition zone developing at the extra-articular tunnel interface [Jackson, D.W. *et al.* (1996) *id ibid.*]. Taking into consideration that hyaline cartilage is naturally developed and maintained only in the joints, where contact with synovial membranes and lubrication with synovial fluid is available and probably essential, it seems reasonable to assume that the environmental conditions in the joint play a major role in enhancing chondrogenesis.

In the following examples the inventors have shown, that a graft composed of DBM and bone marrow cells, together with an RTG polymer, transplanted into a damaged joint or cranial bone, led to successful replacement of damaged cartilage and subchondral bone. This was the result of osteogenesis on the side of contact with bone and chondrogenesis on the free joint surface, thus the physiological environmental conditions favored osteogenesis or chondrogenesis, respectively. The same kind of a graft composed of DBM and bone marrow cells together with an RTG polymer transplanted into experimentally created partial bone defect in the parietal bone of the cranium led to successful replacement of the removed part of the bone. Thus, the new tissue formation follows a differentiation pathway, producing different types of bone and cartilage depending on the local conditions, such that the newly formed tissue meets precisely the local demands.

14729/WO/01

42

The addition of an RTG polymer to the BMC/DBM preparation therefore results in a composition that is injectable at room temperature, but is highly viscous at body temperature and thus forms a depot upon injection, can be employed in non- or minimally invasive techniques and prevent migration of the bioactive components away from the injection site.

Many publications are referred to throughout this application. The contents of all of these references are fully incorporated herein by reference.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise.

The following examples are representative of techniques employed by the inventors in carrying out aspects of the present invention. It should be appreciated that while these techniques are exemplary of preferred embodiments for the practice of the invention, those of skill in the art, in light of the present disclosure, will recognize that numerous modifications can be made without departing from the spirit and intended scope of the invention.

Examples

Experimental Procedures

1. Animals

8 weeks old C57BL/6 male mice and Lewis male rats with body weight of 180-200g were used as the donors of bones (for matrix preparation) and BMC. Animals from the same batches were used as graft recipients.

2. Preparation of demineralized bone matrix (DBM)

Demineralized bone matrix (DBM) was prepared as described [Reddi and Huggins (1973) *id ibid.*] with the inventors' modification. Diaphyseal cortical bone cylinders from Lewis rats were cleaned from bone marrow and surrounding soft tissues, crumbled and placed in a jar with magnetic stirring. Bone chips were rinsed in distilled water for 2-3 hrs; placed in absolute ethanol for 1 hr and in diethyl ether for 0.5 hr, then dried in a laminar flow, pulverized in a mortar with liquid nitrogen and sieved to select particles between 400 and 1,000 μ . The obtained powder was demineralized in 0.6M HCl overnight, washed for several times to remove the acid, dehydrated in absolute ethanol and diethyl ether and dried.

With the exception of the drying step, all steps of the procedure were performed at 4°C, to prevent degradation of Bone Morphogenetic Proteins (BMP) by endogenous proteolytic enzymes. The matrices were stored at -20°C.

3. Preparation of the implanted material

Preparation of donor BMC suspensions for transplantation:

The femurs of donor mice or rats were freed of muscle. Marrow plugs were mechanically pressed out of the femoral canal by a mandrin. Highly concentrated single cell suspensions of BMC were prepared by dissolving 4-5 femoral plugs into 100 μ l of RPMI 1640 medium (Biological Industries, Beit Haemek, Israel), and passing the cells through the needle several times to dissolve the bone marrow tissue into a single-cell suspension. The number of nucleated cells per femoral bone marrow plug is rather stable (about 10⁷ cells/plug for a C57BL/6 male, 8 week old mouse). Several reproducible

verifications have shown that BMC prepared for transplantation in a form of a single cell suspension contains an approximate concentration of 3×10^8 cells/ml.

Preparation of RTG polymeric materials.

Polymer N2

The material is the commercially available Pluronic F-127 Sigma (Catalogue No. P-2443).

Polymer N4

Random [-PEG6000-O-CO-(CH₂)₄-CO-O-PPG3000-]_n poly(ether-ester)

15.3 grams (0.003 mol) of dry PEG6000 (molecular weight 6,000) and 7.4 g (0.003 mol) of PPG3000 were dissolved in 30 ml dry chloroform in a 250 ml flask. 3.2 g pyridine were added to the reaction mixture. Then 2.2 g adipoyl chloride in 20 ml of dry chloroform were added dropwise over a period of 30 min. at 40°C under magnetic stirring. After that, the temperature was risen to 60°C and the reaction was continued for one additional hour and half. The polymer produced was separated from the reaction mixture by adding it to about 600 ml petroleum ether 40-60. The lower phase of the two-phase system produced was separated and dried at RT. Finally, the polymer was washed with portions of petroleum ether and dried, and a light yellow, brittle and water soluble powder was obtained.

Polymer N7

Alternating [-PEG6000-O-CO-O-PPG3000-]_n poly(ether-carbonate)

i) Synthesis of phosgene and preparation of the chloroformic solution

The phosgene was generated by reacting 1,3,5 trioxane (15 g) with carbon tetrachloride (100 g) using aluminum trichloride (30 g) as the catalyst. The phosgene vapors were bubbled in weighed chloroform and the phosgene concentration (w/w) was calculated by weight difference (between 9% and 11%). Due to phosgene's high toxicity, the solution was handled with extreme care and all the work was conducted under a suitable hood.

ii) Synthesis of PEG6000 dichloroformate (ClCO-O-PEG6000-O-COCl)

30.3 grams of dried PEG6000 (molecular weight 6,000) were dissolved in 50 ml dried chloroform in a 250 ml flask. 66 gram of chloroformic solution of phosgene 3% w/w (100% molar excess to PEG) were added to the PEG and the mixture was allowed to react at 60°C for 4h with magnetic stirring and a condenser in order to avoid solvent and phosgene evaporation. The reaction flask was connected to a NaOH trap (20% w/w solution in water/ethanol 1:1) in order to trap the phosgene that could be released during the reaction. Once the reaction was completed, the system was allowed to cool down to RT and the excess of phosgene was eliminated by vacuum. The FT-IR analysis showed the characteristic peak at 1777 cm⁻¹ belonging to the chloroformate group vibration.

iii) Synthesis of alternating [-PEG6000-O-CO-O-PPG3000-]_n poly(ether-carbonate)

15.2 grams of dried PPG3000 (molecular weight 3,000) were added to ClCO-PEG6000-COCl produced in a) at RT. The mixture was cooled to 5°C in an ice bath and 6.3 grams pyridine dissolved in 20 ml chloroform were added dropwise over a 15 min period. Then, the temperature was allowed to heat up to RT and the reaction was continued for additional 45 minutes. After that, the temperature was risen to 35°C and the reaction was continued for one additional hour. The polymer produced was separated from the reaction mixture by adding it to about 600 ml petroleum ether 40-60. The lower phase of the two-phase system produced was separated and dried at RT. Finally, the polymer was washed with portions of petroleum ether and dried, and a light yellow, brittle and water soluble powder was obtained. The material displayed a melting endotherm at 53.5°C and the FT-IR analysis showed the characteristic carbonate group peak at 1746 cm⁻¹. The molecular weight of the polymer produced was M_n 36,400 (M_w/M_n= 1.28), as determined by GPC.

Composition of the grafts:

Grafts were composed of the following ingredients, in different combinations:

1. 10 µl of BMC suspension (concentration 3×10^8 cells/ml);
2. 4 mg of DBM (or MBM);
3. 10 µl of polymeric material solution.

4. Transplantation into the sub-capsular space of the kidney

Anaesthetized rats or mice were used as recipients. A small cut was made in the renal capsule and the transplanted material was inserted using a concave spatula. The transplant consisted of BMC suspension mixed with DBM powder with or w/o the supplement of RTG polymeric material. As a control BMC mixed with polymeric material or RTG polymeric material alone were transferred under the kidney capsule. The skin was closed with stainless clips.

5. Implantation of a mixture of BMC, DBM and polymeric materials into the area of local damage in the articular cartilage of the knee joint

A standard artificial damage in the articular cartilage and subchondral bone in the rat knee joint was induced as described. Following anesthesia, the knee joint was accessed by a medial parapatellar incision, and the patella was temporarily displaced towards the side. A microfracture drilling (for a full thickness defect) of 1.5 mm in diameter and 2.0 mm in depth was made in the intercondylar region of the femur.

The defect was filled with mixture of DBM powder with BMC suspension, prepared as described above, supplemented or not supplemented with polymeric material. As a control BMC mixed with polymeric material or polymeric material alone were transferred into the damaged area. Patella was returned into its place and the incision was sutured with bioresorbable thread. The skin was closed with stainless clips.

6. Implantation of a mixture of BMC, DBM and polymeric materials into the experimentally created calvarial defect.

Lewis rats were anesthetized by intraperitoneal injection of Ketamine. An incision was performed in the frontal region of the rat cranium. The muscular flap was removed from the parietal bone area and a bony defect ($6 \times 6\text{mm}^2$) was made lateral to the sagittal suture using a dental burr. The defect was filled with mixture of DBM powder and BMC suspension, prepared as described above, supplemented or not supplemented with polymeric material. As a control BMC mixed with polymeric material or polymeric material alone were transferred into the damaged area. The skin was closed with stainless clips.

7. Histological evaluation

The autopsied material was fixed in 4% neutral buffered formaldehyde, decalcified, passed through a series of ethanol grades and xylene, and then embedded in paraffin. Serial sections (5-7 microns thick) were obtained. One set of representative serial sections of each sample was stained with Hematoxylin & Eosin (H&E), and another one with Picroindigocarmin (PIC)

Example 1

Study on the influence of various polymeric materials on osteogenic properties of BMC - DBM composition transplanted into the sub-capsular space of the kidney in mice

In the following examples, the experimentation involved in the development of the composition of the invention. Several polymeric materials disposing high viscosity were found to be highly compatible with the process of induced bone development by mesenchymal stem cells persisting in the bone marrow (BM) transplanted together with DBM into the sub-capsular space of the kidney.

The space under the kidney capsule was selected as the site of transplantation, since it has been previously shown that it has no cells, which

14729/WO/01

could be induced into osteogenesis and to build a bone, at least within the period of 2-3 months, thus being able to serve as an *in vivo* experimental tube for study the process of osteogenesis. [Gurevitch, O.A. *et al.* (1989) *Hematol Transfusiol* 34:43-45 (in Russian)].

In several sets of experiments carried out in rats and mice various RTG polymeric materials were studied in transplantation under the kidney capsule for their fitness to criterions mentioned above. The transplant consisted of BMC suspension mixed with DBM powder with or w/o the supplement of RTG polymeric material. As a control BMC mixed with polymeric material or polymeric material alone were transferred into the sub-capsular space of the kidney. No less than 5 transplantations were performed per group.

One month post-transplantation of BMC+DBM together with RTG polymers (NN 2, 4, 7) newly formed cortical and trabecular bone, well developed marrow cavity and functionally active bone marrow are seen in all the cases. No difference in the developmental level of the ectopic ossicles produced by DTM-BMC active complex transplanted with or without mentioned above polymers could be observed (Fig.1).

BMC transplanted without DBM but supplemented with each of the mentioned above RTG polymers produced in most of the cases a small ossicles as it used to be when transplanted BMC are kept together and their migration out of the transplantation site is prevented (Fig.1). It seems most probable that in the absence of osteo-inductive and osteo-conductive influences of DBM mesenchymal stem cells could not be effectively induced into osteogenesis, thus only predifferentiated (restricted to osteo-chondrogenesis) progenitor cells existing in the transplanted BMC are engaged in osteogenesis.

Implantation of the above mentioned polymeric materials alone under the kidney capsule never left any trace in the site of transplantation – neither bone formation nor any side effects such as inflammation etc.

Example 2

Study on the influence of various RTG polymeric materials on correction of experimentally created calvarial defect induced by transplantation of BMC – DBM composition.

Experiments were carried out to test whether the polymeric materials that were chosen in the previous set of experiments for their viscosity and high compatibility with the process of induced bone development by mesenchymal stem cells of BM transplanted together with DBM are able to improve the correction of the experimentally created calvarial defect.

It was shown that transplantation of composition of the invention comprised of BMC, DBM and each of the chosen RTG polymeric materials could initiate and accomplish the intramembranous development of bone, when transplanted into the experimentally created calvarial defect. The results of these experiments are shown in Figs. 3-5. This method could then be extended to treat facial-maxillary defects.

An incision was performed in the frontal cranium region of anesthetized Lewis rats (8-12 weeks old) and the skin flap was moved aside. The muscular flap was removed from the parietal bone area and a bony defect was created laterally to the sagital suture using a dental burr, full width segment of parietal bone ($6 \times 6\text{mm}^2$) was removed. The defect area was filled with BMC suspension mixed with DBM powder with or w/o the supplement of RTG polymeric material. As a control BMC mixed with polymeric material or polymeric material alone were transferred into the experimentally created calvarial defect. The skin flap was returned to place and fixed with stainless clips.

14729/WO/01

50

No less than 5 transplantations were performed per group.

The utilization of non-healing cranial defects allows for the observation of both osteo-conductive and osteo-inductive components of the healing process. Thus, the non-healing cranial defect represents an appropriate model for evaluating the ability of the composition of the present invention to accomplish intramembranous bone formation when transplanted into a damaged area of the crania.

When the site of removed bone was filled with BMC together with each of the investigated RTG polymeric materials, no bone regeneration could be observed 30 days after the operation. It could be clearly seen in x-Ray and Macro pictures and confirmed by histological studies (Fig. 5), suggesting that the size of the defect sufficiently large, compatible with the definition of non-healing cranial defect.

Filling of the experimental cranial defect with each of the polymeric materials alone never left any trace in the site of transplantation – neither bone formation nor any side effects such as inflammation etc.

When BMC-DBM-active composition supplemented with one of the mentioned above RTG polymeric materials was transplanted into the site of the experimental cranial defect, extensive remodeling of the transplanted DBM particles and developing areas of new bone could be observed. As early as one month after transplantation the cut edge of the parietal bone could hardly be distinguished from the surrounding new bony tissue. The defect area was fully reconstituted with a continuous layer of newly developing bone which could be clearly seen in x-Ray and Macro pictures and confirmed by histological studies (Figs. 3 & 4)

It should be especially stressed that extensive remodeling of transplanted DBM particles and active new bone formation were presented evenly throughout the defect area, suggesting that the quantity of available active complex consisting of BMC (containing mesenchymal progenitor cells capable of being induced and conducted to osteogenesis) and DBM particles was maintained uniformly in the defect area.

These findings indicate that supplementation of the active complex composed of BMC and DBM with said RTG polymeric materials i.e. usage the composition of present invention (in this case, DBM together with BMC and said polymeric materials) for transplantation into an experimentally created calvarial defect was sufficient for preventing the transplant from disintegration, keeping the transplant in the proper site preserving its shape, providing active and complete intramembranous bone formation at the site of transplantation. This procedure could be extended to treat facial-maxillary defects.

It has to be especially emphasized that without the application of polymeric materials transplantation of BMC-DBM complex into an experimentally created calvarial defect resulted in non-uniform bone formation suggesting partial disintegration of the transplant and impossibility of keeping its initial shape.

Pilot experiments utilizing BMC in combination with MBM rather than DBM showed positive results. Mainly, the difference between employing DBM and MBM lies on delayed bone formation with MBM. Also, since MBM particles are much more dense and hard, as compared to DBM particles, they are more useful when weight bearing or shape preservation of the transplant are needed. Transplantation of a mixture of both DBM and MBM together with BMC should enable the best of the advantages of both: (a) significantly prolonging the period of osteogenic activity (with DBM acting fast and MBM

after a delay); (b) improving the shape preservation of the implant throughout the whole period of new tissue formation.

Example 3

Study on the influence of various RTG polymeric materials on osteogeneic properties of BMC - DBM composition transplanted into the area of local damage in the articular cartilage of the knee joint.

Experiments were carried out to test whether the polymeric materials that were chosen in the previous set of experiments for their viscosity and high compatibility with the process of induced bone development by mesenchymal stem cells of BM transplanted together with DBM are able to improve the correction of the experimentally damaged osteochondral complex of the knee joint.

It was shown that transplantation of composition of the invention comprised of BMC, DBM and some of the chosen RTG polymeric materials could initiate and accomplish the process bone and cartilage development, when transplanted into the experimentally damaged osteochondral complex of the knee joint. The results of these experiments are shown in Figs. 6-9. This method could then be extended to treat defects in osteochondral complex of the joints.

Male Lewis rats were anesthetized by intraperitoneal injection of Ketamine. Microfracture drilling (full thickness defect) was inflicted in articular cartilage and subchondral bone in the intercondylar region of the femur. The defect area was filled with BMC suspension mixed with DBM powder with or w/o the supplement of RTG polymeric material. As a control BMC mixed with polymeric material or polymeric material alone were transferred into the experimentally created damaged areas of the knee joints. Patella was returned into its place and the incision was sutured with bioresorbable thread. The skin was closed with stainless clips.

No less than 5 transplantations were performed per group.

One month after the site of osteo-chondral defect in the knee joint was filled with DBM-BMC complex together with each of the investigated RTG polymeric materials active regeneration of subchondral bone and hematopoietic cavities, angiogenesis as well as partial degradation and remodeling of DBM particles are seen.

However, the dramatic difference was observed in the way of regeneration of the damaged surface area when different polymeric materials were added. When DBM-BMC complex was transplanted into the damaged area accompanied by RTG polymer N7 regenerating surface was built of thick layer of young hyaline cartilage. On the contrary, when DBM-BMC active complex was transplanted with the supplement of RTG polymers N2 or N4 no cartilage formation was observed, regenerating surface was built of connective tissue.

When BMC together with mentioned above RTG polymeric materials were transplanted into the damaged osteo-chondral complex of the knee joint regeneration followed the same general pattern. Active regeneration of subchondral bone and hematopoietic cavities was seen with all the polymeric materials. However regenerating surface was built of connective tissue alone when BMC were accompanied by RTG polymers N2 or N4, while in the cases in which BMC were supplemented with RTG N7 regenerating surface of the damaged area comprised a mixture of connective tissue with cartilage cells.

Interestingly, RTG polymeric materials N2 and N4 proved to selectively prevent the process of chondrogenesis induced by transplantation of DBM-BMC active complex into the damaged osteochondral area of the knee joint while, being compatible with the process of induced osteogenesis in the same site.

14729/WO/01

54

Two months observation of regeneration patterns of damaged osteochondral complex after DBM-BMC active composition was transplanted supplemented with different RTG polymeric materials completely confirmed the results obtained in one month (Figs. 8 & 9).

It should be stressed that transplantation of the composition of invention (in this case BMC and DBM together with said polymeric materials) into experimentally performed full thickness damage in the osteo-chondral complex of the knee joint allowed to maintain smooth and uniform regenerating surface in the defect area which is especially important for complete rehabilitation of the joint.

These findings indicate that using composition of the present invention (in this case, DBM together with BMC and said RTG polymeric materials) for transplantation into an experimentally created defect in osteo-chondral complex of the knee joint was sufficient for preventing the transplant from disintegration, keeping the transplant in the proper site preventing the DBM particles from thrusting out of the transplantation site into the articular surface, providing formation of fully developed osteochondral complex and the smooth regenerating surface of hyaline cartilage. This procedure could be extended to treat osteo-chondral defects in the joints.

It should be pointed out that without the supplementation with polymeric materials transplantation of BMC-DBM complex into an experimentally created defect in osteo-chondral complex of the knee joint resulted in formation of non-uniform regenerating surface as the result of partial disintegration of the transplant and thrusting of DBM particles out of the site of transplantation into the articular surface of the joint (Fig.10).

Claims:

1. A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) or demineralized tooth matrix (DTM), together with a biodegradable RTG polymer, optionally further comprising pharmaceutically acceptable carrier, additive, diluent and/or excipient.
2. A composition according to claim 1, for use in the transplantation of mesenchymal progenitor cells into any one of a joint, a cranio-facial-maxillary bone, an alveolar bone of maxilla and mandibula, spine, pelvis or long bones of a subject in need.
3. A composition according to claim 1, for use in the construction or reconstruction of an extraskeletal bone of a subject in need.
4. A composition according to claim 1, for use for mechanical or biological support of an artificial implant to a joint or of a joint or to a bone of a subject in need.
5. The composition according to any one of claims 1 to 4, further comprising active agents, preferably selected from a bone morphogenetic proteins (BMPs), an immunosuppressant, an immunomodulator, an antibiotic and an anti-inflammatory agents.
6. The composition according to any one of claims 1 to 4, wherein said RTG polymer comprises hydrophilic and hydrophobic segments covalently bound by at least one chain extender or coupling agent, having at least 2 functional groups, wherein the hydrophilic and hydrophobic segments do not display Reverse Thermal Gelation behavior of their own at body temperature and; wherein the viscosity of said polymeric component increases by at least about 2 times upon exposure to a predetermined trigger.

7. The composition according to any one of claims 1 to 4, wherein said RTG polymer is a segmented block copolymer comprising polyethylene oxide (PEO) and polypropylene oxide (PPO) chains, wherein said PEO and PPO chains are connected via a chain extender, wherein said chain extender is a bifunctional, trifunctional or multifunctional molecule selected from a group consisting of phosgene, aliphatic or aromatic dicarboxylic acids, their reactive derivatives such as acyl chlorides and anhydrides, diamines, diols, aminoacids, oligopeptides, polypeptides, or cyanuric chloride or any other bifunctional, trifunctional or multifunctional coupling agent, or other molecules, synthetic or of biological origin, able to react with the mono, bi, tri or multifunctional -OH, -SH, -COOH, -NH₂, -CN or -NCO group terminated hydrophobic and hydrophilic components or any other bifunctional or multifunctional segment, and/or combinations thereof.

8. The composition according to any one of claims 1 to 4, wherein said RTG polymer is Pluronic^{RTM}, preferably Pluronic F127^{RTM} or F108^{RTM}.

9. The composition according to any one of claims 1 to 4, wherein said RTG polymer is a random [-PEG6000-O-CO-(CH₂)₄-CO-O-PPG3000-]_n poly(ether-ester) or an alternating [-PEG6000-O-CO-O-PPG3000-]_n poly(ether-carbonate).

10. The composition according to any one of claims 2 to 9, wherein said subject is a mammal, preferably a human.

11. The composition according to any one of claims 1 to 10, wherein the DBM is of vertebrate origin.

12. The composition according to claim 11, wherein the DBM is of human origin.

13. The composition according to any one of claims 1 to 12, wherein the DBM is in powder, particles, string or sliced form.

14. The composition according to claim 13, wherein said DMB is in powder or particle form, wherein the particle size of the DBM is about 50 to 2500 μ , preferably about 250 to 500 μ .

15. The composition according to any one of the claims 1 to 14, wherein the ratio between BMC and DBM is between 1:1 and 20:1 (volume:volume), preferably between 2:1 and 9:1 (volume:volume), particularly 4:1 (volume:volume).

16. The composition according to any one of claims 1 to 15, wherein said composition contains BMC-DBM mixture and RTG polymer at a ratio between 5:1 to 1:5, preferably between 3:1 and 1:2, particularly at a ratio of 2 parts BMC-DBM mixture to 1 part of RTG polymer material in fluid form (volume:volume).

17. The composition according to any one of claims 1 to 16, for restoring and/or enhancing the formation of a new hyaline cartilage and/or subchondral bone structure.

18. The composition according to any one of the preceding claims, for the treatment of a patient suffering from any one of hereditary or acquired bone disorder, hereditary or acquired cartilage disorder, a primary malignant bone or cartilage disorder, bone defects due to metastases or bone lesions due to a hematopoietic malignancy, particularly multiple myeloma, metabolic bone diseases, bone infections, conditions involving congenital or acquired bone or cartilage deformities and Paget's disease.

14729/WO/01

58

19. The composition according to any one of claims 1 to 18, for the treatment of a patient in need of any one of correction of complex fractures, bone replacement and formation of new bone in plastic or sexual surgery.
20. The composition according to any one of claims 16 to 19, wherein the number of bone marrow cells in the composition is from about 10^6 to 4×10^{10} cells/ml.
21. A method for transplantation of a mixture comprising BMC with DBM, together with an RTG, and optionally further comprising pharmaceutically acceptable carrier or diluent and/or additional active agent/s, into any one of a joint, a cranio-facial-maxillary bone, an alveolar bone of maxilla and mandibula, spine, pelvis and a long bone, or for construction or reconstruction of an extraskeletal bone, including for mechanical or biological support of artificial implants to a joint or of a joint or to a bone of a subject in need, wherein said method comprises introducing into said joint or bone a composition as defined in any one of claims 1 to 20.
22. The method according to claim 21, wherein said mixture is administered non-invasively by a syringe, an arthroscopic procedure or by open surgery into the site of implantation.
23. A method of treating a damaged joint, post traumatic, inflammatory, autoimmune, infectious or degenerative etiology associated with malformation and/or dysfunction of cartilage and/or subchondral bone in a mammal, preferably a human in need of such treatment, comprising administering into an affected joint or bone of said mammal a composition according to any one of claims 1 to 20.
24. The method according to claim 23, wherein the BMC comprised in said composition are either allogeneic or said mammal's own.

25. A non-invasive implantation method for support of implants of joints or other musculoskeletal implants, comprising introducing a graft into a joint or a crano-facial-maxillary bone of a subject in need, wherein said graft comprises a composition according to any one of claims 1 to 20.

26. Use of a composition according to any one of claims 1 to 20, as a graft of mesenchymal and/or mesenchymal progenitor cells for transplantation/implantation into a mammal, preferably a human.

27. The use according to claim 26, wherein the transplantation is into a joint or into a crano-facial-maxillary bone of said mammal.

28. The use according to any one of claims 26 or 27, wherein said transplantation is for the development of new bone and/or cartilage.

29. The composition according to any one of claims 1 to 20, for use in the treatment of a patient suffering from any one of a hereditary or acquired bone disorder, a hereditary or acquired cartilage disorder, a primary or secondary malignant bone or cartilage disorder, metabolic bone diseases, bone infections, conditions involving bone or cartilage deformities due to traumatic, infectious, inflammatory, autoimmune etiology and Paget's disease.

30. The composition according to any one of claims 1 to 20, for use in the treatment of a patient in need of any one of correction of complex fractures, bone replacement and formation of new bone in plastic and sexual surgery.

31. Use of a mixture of BMC with DBM, together with an RTG polymer, in the preparation of a graft for the treatment of a bone or cartilage disorder.

14729/WO/01

60

32. A kit for performing transplantation of BMC in admixture with DBM and an RTG polymer into any one of a joint, a crano-facial-maxillary bone, an alveolar bone of maxilla and mandibula, spine, pelvis and long bones, or for construction or reconstruction of an extraskeletal bone, including for mechanical or biological support of artificial implants to the joint or of the joint or to the bone of a mammal, wherein said kit comprises:

- (a) DBM in powder, particle, string or slice form;
- (b) a reverse thermogelating polymer (RTG);
- (c) a BM aspiration needle;
- (d) an intra-osseous bone drilling burr;
- (e) a needle with a thick lumen for infusion of viscous bone marrow-DBM-RTG polymer mixture;
- (f) a 2-way lumen connector for simultaneous mixing of BMC with DBM and RTG polymer and diluent;
- (g) a medium for maintaining BMC; and optionally
- (h) additional factors stimulating osteogenesis; and
- (i) cryogenic means for handling and maintaining BMC or BMC together with DBM.

33. The kit according to claim 32, optionally further comprising a carrier and/or diluent for the BMC and DBM mixture, and for the RTG polymer.

ABSTRACT


A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) or demineralized tooth matrix (DTM), together with a reverse thermogelating polymer (RTG), optionally further comprising bone morphogenetic protein/s (BMP) and/or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint or a cranio-facial-maxillary bone, alveolar bone of maxilla and mandibula, spine, pelvis or long bones, or for construction or reconstruction of any extra skeletal bone, including for mechanical or biological support of artificial implants to the joint or of the joint or to the bone, for restoring and/or enhancing the formation of a new hyaline cartilage and subchondral bone structure.

The BMC-DBM-RTG composition of the invention may be used for the treatment of hereditary or acquired bone disorders, hereditary or acquired cartilage disorders, primary or secondary malignant bone or cartilage disorders, metabolic bone diseases, or lesions caused by trauma, infection, any inflammatory process due to unknown or autoimmune etiology, conditions involving bone or cartilage deformities and Paget's disease. The composition may further be used for the correction of complex fractures, bone replacement and formation of new bone in plastic or sexual surgery, for support of implants of joints, cranio-facial-maxillary bones, or other musculoskeletal implants, including any artificial or musculoskeletal implants. The composition may further be used for treating damaged joints or degenerative arthropathy associated with malformation and/or dysfunction of cartilage, subchondral, and/or any other part of the bone.

A kit is provided for performing transplantation of the composition into a joint, maxillary or mandibular alveolar bone or any bony structure of a mammal, including support of artificial implants.

BST/HL 02 / 00736

Figure 1



PCT/L02/00736







Figure 3

X_Ray Macro DBM + BMC + RTG (N2)



PCT/LQ2/0075

OFFICE INO. 17.....

Figure 4




Figure 5




figure 6


DBM + BMC + RTG (N 2)




BMC + RTG (N 2)



DBM + BMC + RTG (N 4)



BMC + RTG (N 4)



ECT/L02/0013

E


H

G

F


PCT/LQ2/00736

Figure 7




PCT/L02 / 00736

Figure 8:



PCT/IL02/00750

Figure 9



PCT/LUZ / UU / JU

SHEET No. 160



B



D



A



C

Figure 10:

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.